Effect of Immune-Enhancing Enteral Nutrition Enriched with or without Beta-Glucan on Immunomodulation in Critically Ill Patients

Lee, Jae; Kim, Young; Lee, Young; Ahn, Hyeon Yeong; Kim, Minjoo; Kim, Minkyung; Cho, Min; Cho, Younsoo; Lee, Jong

doi:10.3390/nu8060336

Cited by 20 publications

(13 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A randomized double-blind placebo-controlled study on 30 critically ill ICU patients, followed for 7 days, found significant increases in NK cell activities when given immune-enhancing enteral nutrition (IMHP) enriched with ß-glucan from the baseline and significantly greater increase than the control group [ 41 ]. The authors suggest that ß-glucan can be an attractive candidate to add to IMPH for stimulation of protective immunity without enhanced inflammation in critically ill patients.…”

Section: Discussionmentioning

confidence: 99%

Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSanTM, on Symptoms, Fatigue and Quality of Life in Patients with Crohn’s Disease in a Randomized Single-Blinded Placebo Controlled Study

et al. 2016

View full text Add to dashboard Cite

BackgroundIngestion of AndoSanTM, based on the mushroom Agaricus blazei Murill, has previously shown an anti-inflammatory effect through reduction of pro-inflammatory cytokines in healthy individuals and patients with Crohn’s disease (CD). In this randomized single-blinded placebo-controlled study we examined whether intake of AndoSanTM also resulted in clinical effects.Methods and Findings50 patients with symptomatic CD were randomized for oral daily consumption of AndoSanTM or placebo for a 21-day experimental period, in this per-protocol study. Patients reported validated scores for symptoms, fatigue and health related quality of life (HRQoL) at days 0, 14 and 21. Fecal calprotectin and general blood parameters were also analyzed. In the AndoSanTM group (n = 25) symptoms improved from baseline (day 0) to days 14 and 21, with respective mean scores (95% CI) of 5.52 (4.64–6.40), 4.48 (3.69–5.27) and 4.08 (3.22–4.94) (p<0,001). We found significant improvements in symptom score for both genders in the AndoSanTM group, and no significant changes in the placebo (n = 25) group. There were however no significant differences between the groups (p = 0.106), although a marginal effect in symptom score for men (p = 0.054). There were comparable improvements in physical, mental and total fatigue for both groups. HRQoL versus baseline were at day 21 improved for bodily pain and vitality in the AndoSanTM group and for vitality and social functioning in the placebo group. No crucial changes in general blood samples and fecal calprotectin were detected.ConclusionsThe results from this single-blinded randomized clinical trial shows significant improvement on symptoms, for both genders, in the AndoSanTM group, but no significant differences between the study groups. The results on fatigue, HRQoL, fecal calprotectin and blood samples were quite similar compared with placebo. The patients did not report any harms or unintended effects of AndoSanTM. CD patients with mild to moderate symptoms may have beneficiary effects of AndoSanTM as a safe supplement in addition to conventional medication.Trial RegistrationClinicalTrials.gov NCT01496053

show abstract

Section: Discussionmentioning

confidence: 99%

Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSanTM, on Symptoms, Fatigue and Quality of Life in Patients with Crohn’s Disease in a Randomized Single-Blinded Placebo Controlled Study

et al. 2016

View full text Add to dashboard Cite

show abstract

“…Anthropometric parameters, serum lipid profiles, glucose, nutritional status, liver and renal function tests, cytokine levels in serum and PBMC supernatants, and NK cell activity were analyzed as previously described [ 25 ]. Detailed information about assessments of cytokine levels in serum and PBMC supernatants, and NK cell activity were described in supplementary information (See Additional File 1).…”

Section: Methodsmentioning

confidence: 99%

Hyporesponsiveness of natural killer cells and impaired inflammatory responses in critically ill patients

et al. 2017

Self Cite

View full text Add to dashboard Cite

BackgroundTo investigate natural killer (NK) cell activity, circulating cytokine level and peripheral blood mononuclear cell (PBMC) cytokine production status in critically ill patients.MethodsBlood samples were collected <24 h after admission from 24 intensive care unit (ICU) patients and 24 age-, sex-, and body mass index (BMI)-matched healthy controls. Serum cytokine concentrations and cytokine production by PBMCs and lipopolysaccharide (LPS)-stimulated PBMCs were measured.ResultsThe ICU group showed lower NK cell activity than the controls under all conditions and an absence of interferon (IFN)-γ. After adjusting for triglycerides, LDL- and HDL-cholesterol, and glucose, the ICU group exhibited lower serum levels of albumin and interleukin (IL)-12 and higher leukocyte counts and hs-CRP and IL-6 levels than the controls. Non-stimulated PBMCs from ICU patients secreted significantly greater amounts of IL-6 and IL-1β than the controls; however, the production of IL-6, TNF-α and IL-1β in response to LPS stimulation was significantly lower in the ICU group.ConclusionsSignificant reductions in NK cell activity and serum IL-12 level, an absence of serum IFN-γ, and decreased cytokine production from LPS-stimulated PBMCs indicate the hyporesponsiveness of NK cells and an impaired early phase inflammatory response in critically ill patients (ClinicalTrials.gov NCT02565589:). Retrospectively registered; October 1, 2015.

show abstract

“…Lee et al studied the immunomodulating effects of nutrients enriched with β-glucans in critically ill patients with pulmonary disease and trauma [ 160 ]. In a randomized, double-blind, placebo-controlled study, β-glucan-enriched fractions showed an increase in natural killer cell activities and serum albumin.…”

Section: Immunomodulating Effects Of β-Glucansmentioning

confidence: 99%

Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future

Bashir

Choi

2017

IJMS

179

107

View full text Add to dashboard Cite

β-Glucans are a group of biologically-active fibers or polysaccharides from natural sources with proven medical significance. β-Glucans are known to have antitumor, anti-inflammatory, anti-obesity, anti-allergic, anti-osteoporotic, and immunomodulating activities. β-Glucans are natural bioactive compounds and can be taken orally, as a food supplement, or as part of a daily diet, and are considered safe to use. The medical significance and efficiency of β-glucans are confirmed in vitro, as well as using animal- and human-based clinical studies. However, systematic study on the clinical and physiological significance of β-glucans is scarce. In this review, we not only discuss the clinical and physiological importance of β-glucans, we also compare their biological activities through the existing in vitro and animal-based in vivo studies. This review provides extensive data on the clinical study of β-glucans.

show abstract

Effect of Immune-Enhancing Enteral Nutrition Enriched with or without Beta-Glucan on Immunomodulation in Critically Ill Patients

Cited by 20 publications

References 38 publications

Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSanTM, on Symptoms, Fatigue and Quality of Life in Patients with Crohn’s Disease in a Randomized Single-Blinded Placebo Controlled Study

Effect of the Medicinal Agaricus blazei Murill-Based Mushroom Extract, AndoSanTM, on Symptoms, Fatigue and Quality of Life in Patients with Crohn’s Disease in a Randomized Single-Blinded Placebo Controlled Study

Hyporesponsiveness of natural killer cells and impaired inflammatory responses in critically ill patients

Clinical and Physiological Perspectives of β-Glucans: The Past, Present, and Future

Contact Info

Product

Resources

About